Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCG101 in HBV-Related Hepatocellular Carcinoma
NCT06617000Phase 1Recruiting
- Sponsor
- SCG Cell Therapy
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SCG101 in hepatocellular carcinoma (HCC), sponsored by SCG Cell Therapy. Primary endpoints: Incidence of dose-limiting toxicity and adverse events at 12 months, Preliminary clinical efficacy at 12 months and 2 more. Started Oct 2022; status: recruiting.
02
Drugs
SCG101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06617000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617000.